Androgen receptor modulator

A randomised, double-blind, placebo controlled phase IIB trial has shown that treatment with Enobosarm, a non-steroidal selective androgen receptor modulator,...


Researchers have reported new evidence to explain why prostate cancer and other hormone-dependent cancers may become resistant to hormone therapies....